COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

NCT04852978 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

295

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Chronic Stable Illness

Interventions

DRUG: casirivimab+imdevimab
BIOLOGICAL: Moderna mRNA-1273 vaccine

Sponsor

Regeneron Pharmaceuticals